Recent SILO News
- Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic • GlobeNewswire Inc. • 03/20/2024 12:30:00 PM
- Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain • GlobeNewswire Inc. • 03/18/2024 11:15:00 AM
- Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD • GlobeNewswire Inc. • 02/28/2024 01:25:00 PM
- Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery • GlobeNewswire Inc. • 02/14/2024 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 06:15:35 PM
- Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology • GlobeNewswire Inc. • 02/01/2024 03:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/31/2024 05:15:16 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:29:45 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:27:04 PM
- Silo Pharma Announces Positive Results in Alzheimer’s Disease Study • GlobeNewswire Inc. • 01/24/2024 01:55:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/23/2024 10:01:06 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/11/2024 05:15:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 09:30:11 PM
- Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD • GlobeNewswire Inc. • 01/04/2024 01:55:00 PM
- Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia • GlobeNewswire Inc. • 12/28/2023 01:25:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/21/2023 09:13:38 PM
- Form 8-K12B - Notification that a class of securities of successor issuer is deemed to be registered pursuant to section 12(b) • Edgar (US Regulatory) • 12/20/2023 09:58:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:44:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/07/2023 11:13:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:05:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 09:55:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/01/2023 02:10:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 10:13:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 09:01:10 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM